• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

在细菌中产生的广谱中和抗体片段控制 HIV 的探索。

Exploration of broadly neutralizing antibody fragments produced in bacteria for the control of HIV.

机构信息

a Department of Microbiology and Immunology , The University of Melbourne, Peter Doherty Institute for Infection and Immunity , Victoria , Australia.

b Affinity BIO Pty Ltd. , Melbourne , VIC , Australia.

出版信息

Hum Vaccin Immunother. 2017 Nov 2;13(11):2726-2737. doi: 10.1080/21645515.2017.1368935. Epub 2017 Sep 26.

DOI:10.1080/21645515.2017.1368935
PMID:28949787
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5703365/
Abstract

While broadly neutralizing antibodies (bnAbs) are a promising preventative and therapeutic tool for HIV infection, production is difficult and expensive. Production of antibody-like fragments in bacterial cytoplasm provides a cheaper alternative. This work explored the transplantation of the complementarity determining regions of the anti-HIV bnAbs PGT121 and 10E8 onto a single-chain variable fragment (scFv) scaffold, previously discovered through a novel screening platform. The scaffolded 10E8 scFv, but not the scaffolded PGT121 scFv, was soluble in bacterial cytoplasm, enabling efficient production in bacteria. Three additional multimeric constructs employing the scaffolded 10E8 scFv were also generated and soluble versions produced in bacteria. However, the constructs were found to have substantially lost anti-HIV binding function and had completely abrogated neutralizing activity. Overall, while this study provides a proof-of-concept for anti-HIV bnAb construct production in bacterial cytoplasm, future refinement of these technologies will be required to realize the goal of producing inexpensive and effective bnAb-like tools for the control of HIV.

摘要

虽然广泛中和抗体 (bnAbs) 是一种有前途的预防和治疗 HIV 感染的工具,但它们的生产既困难又昂贵。在细菌细胞质中生产抗体样片段提供了一种更便宜的替代方法。这项工作探索了将抗 HIV bnAbs PGT121 和 10E8 的互补决定区移植到先前通过新型筛选平台发现的单链可变片段 (scFv) 支架上。支架化的 10E8 scFv,但不是支架化的 PGT121 scFv,可溶于细菌细胞质中,从而能够在细菌中高效生产。还生成了另外三个使用支架化的 10E8 scFv 的多聚体构建体,并在细菌中生产出可溶性版本。然而,发现这些构建体的抗 HIV 结合功能大大丧失,并且完全丧失了中和活性。总的来说,尽管这项研究为在细菌细胞质中生产抗 HIV bnAb 构建体提供了一个概念验证,但未来需要进一步改进这些技术,以实现生产廉价且有效的 bnAb 样工具来控制 HIV 的目标。

相似文献

1
Exploration of broadly neutralizing antibody fragments produced in bacteria for the control of HIV.在细菌中产生的广谱中和抗体片段控制 HIV 的探索。
Hum Vaccin Immunother. 2017 Nov 2;13(11):2726-2737. doi: 10.1080/21645515.2017.1368935. Epub 2017 Sep 26.
2
A microbial expression system for high-level production of scFv HIV-neutralizing antibody fragments in Escherichia coli.一种在大肠杆菌中高效表达 scFv HIV 中和抗体片段的微生物表达系统。
Appl Microbiol Biotechnol. 2019 Nov;103(21-22):8875-8888. doi: 10.1007/s00253-019-10145-1. Epub 2019 Oct 22.
3
Neutralization Breadth and Potency of Single-Chain Variable Fragments Derived from Broadly Neutralizing Antibodies Targeting Multiple Epitopes on the HIV-1 Envelope.针对 HIV-1 包膜上多个表位的广泛中和抗体的单链可变片段的中和广度和效力。
J Virol. 2020 Jan 6;94(2). doi: 10.1128/JVI.01533-19.
4
Single-Chain Variable Fragments of Broadly Neutralizing Antibodies Prevent HIV Cell-Cell Transmission.单链可变片段抗体可预防 HIV 细胞间传播。
J Virol. 2022 Feb 23;96(4):e0193421. doi: 10.1128/jvi.01934-21. Epub 2021 Dec 22.
5
Rational design of a trispecific antibody targeting the HIV-1 Env with elevated anti-viral activity.一种具有增强抗病毒活性的靶向HIV-1包膜糖蛋白的三特异性抗体的合理设计。
Nat Commun. 2018 Feb 28;9(1):877. doi: 10.1038/s41467-018-03335-4.
6
Potential of conventional & bispecific broadly neutralizing antibodies for prevention of HIV-1 subtype A, C & D infections.传统和双特异性广谱中和抗体预防 HIV-1 亚型 A、C 和 D 感染的潜力。
PLoS Pathog. 2018 Mar 5;14(3):e1006860. doi: 10.1371/journal.ppat.1006860. eCollection 2018 Mar.
7
Enhanced Ability of Plant-Derived PGT121 Glycovariants To Eliminate HIV-1-Infected Cells.植物来源的 PGT121 糖型变体增强清除感染 HIV-1 细胞的能力。
J Virol. 2021 Aug 25;95(18):e0079621. doi: 10.1128/JVI.00796-21.
8
Engineered Expression of Broadly Neutralizing Antibodies Against Human Immunodeficiency Virus.工程化表达广谱中和抗体抗人类免疫缺陷病毒。
Annu Rev Virol. 2017 Sep 29;4(1):491-510. doi: 10.1146/annurev-virology-101416-041929. Epub 2017 Jun 23.
9
Combinations of Single Chain Variable Fragments From HIV Broadly Neutralizing Antibodies Demonstrate High Potency and Breadth.HIV 广谱中和抗体的单链可变片段组合具有高效力和广谱性。
Front Immunol. 2021 Sep 16;12:734110. doi: 10.3389/fimmu.2021.734110. eCollection 2021.
10
Cell membrane-anchored anti-HIV single-chain antibodies and bifunctional inhibitors targeting the gp41 fusion protein: new strategies for HIV gene therapy.细胞膜锚定的抗 HIV 单链抗体和针对 gp41 融合蛋白的双功能抑制剂:HIV 基因治疗的新策略。
Emerg Microbes Infect. 2022 Dec;11(1):30-49. doi: 10.1080/22221751.2021.2011616.

引用本文的文献

1
A systems approach to elucidate personalized mechanistic complexities of antibody-Fc receptor activation post-vaccination.采用系统方法阐明疫苗接种后抗体-Fc 受体激活的个体化机制复杂性。
Cell Rep Med. 2021 Sep 1;2(9):100386. doi: 10.1016/j.xcrm.2021.100386. eCollection 2021 Sep 21.

本文引用的文献

1
Broadly Neutralizing Antibodies for HIV-1 Prevention or Immunotherapy.用于预防或免疫治疗HIV-1的广泛中和抗体。
N Engl J Med. 2016 Nov 24;375(21):2019-2021. doi: 10.1056/NEJMp1613362. Epub 2016 Nov 9.
2
Early short-term treatment with neutralizing human monoclonal antibodies halts SHIV infection in infant macaques.用中和性人单克隆抗体进行早期短期治疗可阻止幼龄猕猴感染猴免疫缺陷病毒。
Nat Med. 2016 Apr;22(4):362-8. doi: 10.1038/nm.4063. Epub 2016 Mar 21.
3
Cross-Neutralization Activity of Single-Chain Variable Fragment (scFv) Derived from Anti-V3 Monoclonal Antibodies Mediated by Post-Attachment Binding.由附着后结合介导的抗V3单克隆抗体衍生的单链可变片段(scFv)的交叉中和活性
Jpn J Infect Dis. 2016 Sep 21;69(5):395-404. doi: 10.7883/yoken.JJID.2015.667. Epub 2016 Feb 19.
4
Virologic effects of broadly neutralizing antibody VRC01 administration during chronic HIV-1 infection.广泛中和抗体 VRC01 在慢性 HIV-1 感染期间的病毒学效应。
Sci Transl Med. 2015 Dec 23;7(319):319ra206. doi: 10.1126/scitranslmed.aad5752.
5
Safety, pharmacokinetics and neutralization of the broadly neutralizing HIV-1 human monoclonal antibody VRC01 in healthy adults.健康成年人中广泛中和HIV-1的人单克隆抗体VRC01的安全性、药代动力学及中和作用
Clin Exp Immunol. 2015 Dec;182(3):289-301. doi: 10.1111/cei.12692. Epub 2015 Sep 24.
6
Challenges to production of antibodies in bacteria and yeast.在细菌和酵母中生产抗体所面临的挑战。
J Biosci Bioeng. 2015 Nov;120(5):483-90. doi: 10.1016/j.jbiosc.2015.03.009. Epub 2015 Apr 23.
7
Viraemia suppressed in HIV-1-infected humans by broadly neutralizing antibody 3BNC117.在HIV-1感染的人类中,广谱中和抗体3BNC117可抑制病毒血症。
Nature. 2015 Jun 25;522(7557):487-91. doi: 10.1038/nature14411. Epub 2015 Apr 8.
8
Bacterial cytoplasmic display platform Retained Display (ReD) identifies stable human germline antibody frameworks.
Biotechnol J. 2015 May;10(5):783-9. doi: 10.1002/biot.201400560. Epub 2015 Mar 20.
9
Intra-spike crosslinking overcomes antibody evasion by HIV-1.刺突内交联克服了HIV-1的抗体逃逸。
Cell. 2015 Jan 29;160(3):433-46. doi: 10.1016/j.cell.2015.01.016.
10
Escherichia coli surface display of single-chain antibody VRC01 against HIV-1 infection.用于抗HIV-1感染的单链抗体VRC01在大肠杆菌表面的展示
Virology. 2015 Jan 15;475:179-86. doi: 10.1016/j.virol.2014.11.018. Epub 2014 Dec 5.